Version history

{
  "description": "## Mechanistic Overview\nNutrient-Sensing Epigenetic Circuit Reactivation starts from the claim that modulating SIRT1 within the disease context of neurodegeneration can redirect a disease-relevant process. The original description reads: \"**Molecular Mechanism and Rationale** The nutrient-sensing epigenetic circuit centered on AMPK-SIRT1-PGC1α represents a fundamental regulatory network that governs cellular energy homeostasis and metabolic adaptation. In aging neurons, this circuit becomes progressively silenced through multiple epigenetic modifications, leading to impaired mitochondrial biogenesis, reduced autophagy, and compromised cellular quality control mechanisms. The core hypothesis proposes that targeted epigenetic reactivation of SIRT1 (Silent Information Regulator T1) can restore the entire nutrient-sensing cascade and reverse key metabolic aspects of neuronal aging. At the molecular level, SIRT1 functions as a NAD+-dependent histone deacetylase that serves as a critical metabolic sensor linking cellular energy status to transcriptional regulation. Under nutrient-limited conditions, elevated NAD+/NADH ratios activate SIRT1, which subsequently deacetylates and activates PGC1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) at lysine residues K13 and K779. This deacetylation event triggers PGC1α's coactivator function, promoting the transcription of mitochondrial biogenesis genes including NRF1, NRF2, and TFAM (transcription factor A, mitochondrial). Simultaneously, SIRT1 deacetylates p53 at K382, reducing its pro-apoptotic activity, and deacetylates FOXO transcription factors, enhancing their ability to promote stress resistance genes. The AMPK-SIRT1 connection occurs through multiple nodes: AMPK activation phosphorylates and activates PGC1α at Thr177 and Ser538, while simultaneously increasing NAD+ levels through enhanced fatty acid oxidation, creating a positive feedback loop that amplifies SIRT1 activity. Additionally, AMPK directly phosphorylates acetyl-CoA carboxylase (ACC), reducing malonyl-CoA production and relieving inhibition of CPT1 (carnitine palmitoyltransferase I), thereby enhancing mitochondrial fatty acid oxidation and further increasing NAD+ availability. During aging, multiple factors contribute to circuit silencing: decreased NAD+ biosynthesis due to reduced NAMPT (nicotinamide phosphoribosyltransferase) expression, increased inflammatory signaling that promotes SIRT1 protein degradation via the ubiquitin-proteasome system, and hypermethylation of the SIRT1 promoter region, particularly at CpG sites -300 to -100 bp upstream of the transcription start site. These age-related changes create a vicious cycle where reduced SIRT1 activity leads to mitochondrial dysfunction, increased oxidative stress, and further epigenetic silencing of the nutrient-sensing network. **Preclinical Evidence** Extensive preclinical evidence supports the therapeutic potential of reactivating the AMPK-SIRT1-PGC1α axis in neurodegeneration models. In 5xFAD transgenic mice, a well-established Alzheimer's disease model harboring five familial AD mutations, treatment with the SIRT1 activator SRT1720 demonstrated remarkable neuroprotective effects. Specifically, 12-week treatment beginning at 6 months of age resulted in a 45-60% reduction in cortical and hippocampal amyloid plaque burden, accompanied by improved performance in Morris water maze testing (escape latency reduced from 65±8 seconds to 35±6 seconds in treated animals versus untreated controls). In vitro studies using primary cortical neurons from APP/PS1 transgenic mice revealed that SIRT1 overexpression increased mitochondrial biogenesis markers by 2.5-fold, including TFAM, COX IV, and citrate synthase activity. Oxygen consumption rates measured by Seahorse extracellular flux analysis showed 40% higher maximal respiratory capacity in SIRT1-overexpressing neurons compared to controls. Critically, these metabolic improvements correlated with enhanced amyloid-beta clearance through both proteasomal and autophagic pathways, with LC3-II/LC3-I ratios increasing 3-fold and p62 levels decreasing by 60%. Studies in Caenorhabditis elegans expressing human tau (strain CL2006) demonstrated that daf-16 (the worm FOXO ortholog) overexpression extended lifespan by 35% and reduced tau-induced paralysis from 8 days to 12 days post-hatching. Importantly, these benefits required sir-2.1 (the worm SIRT1 ortholog), confirming evolutionary conservation of the nutrient-sensing pathway's neuroprotective functions. In Drosophila models of Huntington's disease expressing mutant huntingtin with 128 CAG repeats, genetic enhancement of dSir2 (fly SIRT1) or pharmacological activation with resveratrol improved climbing ability by 50% and reduced aggregate formation in photoreceptor neurons by 40%. Mitochondrial DNA copy number, a marker of mitochondrial biogenesis, increased 2.8-fold in treated flies, while ATP levels were restored to 85% of wild-type controls compared to 45% in untreated mutants. Mechanistic studies using SIRT1 knockout mice revealed age-accelerated phenotypes including premature synaptic dysfunction, with 40% reduction in long-term potentiation amplitude in hippocampal slices from 6-month-old SIRT1-/- mice compared to age-matched controls. These findings directly implicate SIRT1 deficiency in age-related neuronal dysfunction and validate the circuit as a therapeutic target. **Therapeutic Strategy and Delivery** The therapeutic approach centers on small molecule SIRT1 activators, particularly next-generation compounds that demonstrate improved potency and selectivity over first-generation molecules like resveratrol. Lead compound SRT2104, a synthetic SIRT1 activator with 1000-fold greater potency than resveratrol, has shown excellent CNS penetration with brain-to-plasma ratios of 0.6-0.8 in rodent models. The compound demonstrates dose-dependent SIRT1 activation with an EC50 of 0.16 μM and exhibits favorable pharmacokinetic properties including 85% oral bioavailability and a 12-hour half-life. Alternative delivery strategies include NAD+ precursors such as nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), which indirectly activate SIRT1 by increasing substrate availability. NR supplementation at 400 mg twice daily has demonstrated the ability to increase brain NAD+ levels by 60% in aged mice, with corresponding improvements in mitochondrial function and neuronal survival. The advantage of NAD+ precursor therapy lies in its ability to enhance the entire NAD+-dependent enzyme family, including SIRT1, SIRT3, and PARP1, providing broader metabolic benefits. For enhanced CNS delivery, lipid nanoparticle formulations have been developed that increase brain uptake by 3-4 fold compared to free drug. These formulations utilize phosphatidylserine and cholesterol to mimic natural membrane composition and facilitate crossing of the blood-brain barrier. Alternatively, intranasal delivery bypasses systemic circulation and achieves direct CNS access via the olfactory and trigeminal nerve pathways, with peak brain concentrations occurring within 30 minutes of administration. Dosing considerations are based on achieving sustained SIRT1 activation while avoiding potential side effects. Preclinical dose-response studies suggest an optimal range of 50-100 mg/kg for SRT2104 in mouse models, translating to approximately 4-8 mg/kg in humans based on allometric scaling. Chronic dosing studies over 12 months in non-human primates showed no significant adverse effects at doses up to 3000 mg/day, establishing a substantial safety margin. **Evidence for Disease Modification** Multiple biomarker and functional outcome measures distinguish disease-modifying effects from symptomatic treatment. Neuroimaging studies using [18F]FDG-PET demonstrate restored glucose metabolism in brain regions typically hypometabolic in neurodegeneration. In APP/PS1 mice treated with SIRT1 activators, glucose uptake increased by 35% in hippocampus and 28% in frontal cortex, correlating with improved cognitive performance and reduced neuroinflammation markers. Cerebrospinal fluid biomarkers provide additional evidence of disease modification. Treatment with SIRT1 activators reduces phosphorylated tau levels by 40-50% and increases Aβ42/Aβ40 ratios, suggesting improved amyloid processing. Importantly, these changes occur independently of acute cognitive effects, indicating modification of underlying pathological processes rather than symptomatic enhancement. Structural MRI studies in treated animals show preservation of hippocampal and cortical volumes, with 20-25% less atrophy compared to vehicle-treated controls after 6 months of treatment. Diffusion tensor imaging reveals maintained white matter integrity, with fractional anisotropy values remaining within 10% of healthy controls versus 35% reduction in untreated animals. Functional outcomes include restoration of synaptic plasticity measured by long-term potentiation recording in hippocampal slices. Treated animals show LTP amplitudes of 180±15% of baseline compared to 125±10% in untreated aged mice, approaching values seen in young animals (195±12%). These electrophysiological improvements correlate with increased expression of synaptic proteins including PSD95, synaptophysin, and NMDA receptor subunits. Mitochondrial function biomarkers provide mechanistic validation of therapeutic effects. Muscle biopsy studies in treated animals show increased mitochondrial DNA copy number, enhanced complex I and IV activities, and improved ATP synthesis rates. These peripheral changes likely reflect systemic metabolic improvements that support central nervous system function. **Clinical Translation Considerations** Patient selection strategies focus on early-stage neurodegenerative disease where metabolic dysfunction is present but extensive neuronal loss has not yet occurred. Ideal candidates include individuals with mild cognitive impairment, early Alzheimer's disease (CDR 0.5-1.0), or genetic risk factors such as APOE4 carriers showing metabolic biomarker abnormalities. Exclusion criteria include advanced dementia (MMSE <15), significant medical comorbidities affecting metabolism (uncontrolled diabetes, liver disease), and concurrent medications that interfere with NAD+ metabolism. Trial design considerations emphasize enrichment strategies using metabolic biomarkers. Screening for reduced NAD+ levels, impaired glucose metabolism on PET imaging, or elevated inflammatory markers may identify patients most likely to respond. A proposed Phase 2 trial would randomize 200 mild AD patients to SIRT1 activator versus placebo for 18 months, with primary endpoints including change in CDR-SB scores and hippocampal volume by MRI. Safety considerations are paramount given the chronic dosing required. Preclinical toxicology studies identified potential concerns including mild hypoglycemia in diabetic animals and transient elevation of liver enzymes at high doses. Human safety studies with related compounds have been generally favorable, though careful monitoring of glucose homeostasis and hepatic function is essential. Drug interactions may occur with medications affecting NAD+ metabolism, including niacin supplements and certain antibiotics. The regulatory pathway follows traditional drug development with emphasis on biomarker qualification. The FDA's accelerated approval pathway may be applicable if robust biomarker changes correlate with clinical benefit. International regulatory harmonization through ICH guidelines will facilitate global development, while orphan drug designation may be possible for specific genetic forms of neurodegeneration. Competitive landscape analysis reveals multiple approaches targeting aging mechanisms, including mTOR inhibitors, senolytic agents, and mitochondrial-targeted therapeutics. The SIRT1 activation approach offers advantages in terms of established safety profile and multiple mechanisms of action, though direct comparison studies will be necessary to establish relative efficacy. **Future Directions and Combination Approaches** Future research directions encompass both mechanistic understanding and therapeutic optimization. Advanced epigenetic profiling using ChIP-seq and ATAC-seq will map genome-wide changes in chromatin accessibility following SIRT1 activation, identifying additional therapeutic targets within the nutrient-sensing network. Single-cell RNA sequencing of treated brain tissue will reveal cell-type-specific responses and guide precision medicine approaches. Combination therapy strategies hold particular promise for enhancing therapeutic efficacy. The integration of SIRT1 activators with AMPK activators such as metformin or specific agonists like AICAR may create synergistic effects on metabolic restoration. Preliminary studies suggest that combined treatment increases therapeutic benefits by 40-60% compared to monotherapy approaches. Novel delivery technologies including focused ultrasound-mediated blood-brain barrier opening may enhance CNS drug penetration and allow for lower systemic doses. Gene therapy approaches using adeno-associated virus vectors to deliver SIRT1 or PGC1α directly to affected brain regions represent another frontier, potentially providing more durable therapeutic effects. The application of this approach extends beyond classical neurodegenerative diseases to include metabolic aspects of psychiatric disorders, age-related cognitive decline, and traumatic brain injury. The fundamental role of metabolic dysfunction in these conditions suggests broad therapeutic applicability of nutrient-sensing pathway reactivation. Biomarker development continues to evolve, with advanced metabolomics identifying NAD+ metabolite signatures that predict treatment response. Wearable devices capable of monitoring metabolic parameters may enable personalized dosing adjustments and early detection of therapeutic effects. The integration of artificial intelligence and machine learning will optimize patient selection and predict individual treatment responses based on multi-omic data integration. --- ## Mechanism Pathway ```mermaid flowchart TD A[\"Aging Neurons:<br/>NAD⁺ Decline\"] --> B[\"SIRT1 Activity<br/>Reduced\"] B --> C[\"AMPK-SIRT1-PGC1alpha<br/>Circuit Silenced\"] C --> D[\"Epigenetic Marks:<br/>H3K9me3, DNA Methylation\"] D --> E[\"SIRT1 Promoter<br/>Silenced\"] C --> F[\"Impaired Mitochondrial<br/>Biogenesis\"] C --> G[\"Reduced Autophagy\"] F --> H[\"Metabolic Dysfunction<br/>& ROS Accumulation\"] G --> I[\"Protein Aggregate<br/>Accumulation\"] H --> J[\"Neurodegeneration\"] I --> J K[\"🎯 Intervention:<br/>NMN/NR + SIRT1<br/>Activators\"] --> L[\"NAD⁺ Restoration\"] L --> M[\"SIRT1 Reactivation\"] K --> N[\"Epigenetic Editing:<br/>CRISPR-dCas9-TET1\"] N --> O[\"Demethylate SIRT1<br/>Promoter\"] M --> P[\"PGC1alpha Deacetylation<br/>& Activation\"] O --> P P --> Q[\"Mitochondrial Biogenesis<br/>& Autophagy Restored\"] Q --> R[\"Neuronal Metabolic<br/>Recovery\"] style A fill:#e57373,color:#fff style D fill:#ff8a65,color:#fff style J fill:#c62828,color:#fff style K fill:#66bb6a,color:#fff style R fill:#2e7d32,color:#fff ``` --- ## Key References 1. **AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies From Energy Homeostasis Regulation to Disease Therapy.** — Chen J et al. *CNS Neurosci Ther* (2025) [PMID:41268687](https://pubmed.ncbi.nlm.nih.gov/41268687/)\" Framed more explicitly, the hypothesis centers SIRT1 within the broader disease setting of neurodegeneration. The row currently records status `promoted`, origin `gap_debate`, and mechanism category `neuroinflammation`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.\nThe decision-relevant question is whether modulating SIRT1 or the surrounding pathway space around Sirtuin-1 / NAD+ metabolism / deacetylation can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.\nSciDEX scoring currently records confidence 0.85, novelty 0.70, feasibility 0.95, impact 0.85, mechanistic plausibility 0.90, and clinical relevance 0.12.\n\n## Molecular and Cellular Rationale\nThe nominated target genes are `SIRT1` and the pathway label is `Sirtuin-1 / NAD+ metabolism / deacetylation`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.\nGene-expression context on the row adds an important constraint: **Gene Expression Context** **SIRT1 (Sirtuin 1):** - Highly expressed in hippocampal CA1 neurons and cortical layers II/III (Allen Human Brain Atlas) - 40-60% reduction in SIRT1 protein in AD temporal cortex (Braak stage V-VI vs controls) - Nuclear-to-cytoplasmic redistribution in neurons with tau pathology - SIRT1 mRNA relatively preserved; dysfunction primarily post-translational (NAD+ depletion) **NAMPT (Nicotinamide Phosphoribosyltransferase):** - Enriched in neurons > astrocytes > microglia (Human Cell Atlas, brain) - 30-40% reduced in AD cortex, correlates with cognitive decline (r = 0.62) - Circadian expression pattern: peaks during active phase, declines during sleep - Extracellular NAMPT (eNAMPT) declines with age in CSF **CD38 (NAD+ Glycohydrolase):** - Low baseline in neurons; high in activated microglia and reactive astrocytes - 2-3× upregulated in AD brain microglia (SEA-AD single-cell data) - Major driver of age-related NAD+ decline (CD38 KO mice maintain youthful NAD+) - Expression inversely correlates with tissue NAD+ levels (r = -0.71) **PGC-1α (PPARGC1A):** - Highest expression in high-energy neurons: substantia nigra, hippocampal pyramidal - 50-65% reduced in AD hippocampus; correlates with mitochondrial gene downregulation - Exercise induces PGC-1α in hippocampus via FNDC5/irisin pathway - Allen Mouse Brain Atlas: enriched in CA1, dentate gyrus, cerebellar Purkinje cells **PARP1:** - Ubiquitous nuclear expression; hyperactivated in neurons with DNA damage - AD neurons show 3-5× increased PARP1 activity vs age-matched controls - PARP1 hyperactivation accounts for ~30% of NAD+ consumption in damaged neurons - Competitive inhibitor of SIRT1 for NAD+ substrate This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.\nWithin neurodegeneration, the working model should be treated as a circuit of stress propagation. Perturbation of SIRT1 or Sirtuin-1 / NAD+ metabolism / deacetylation is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.\n\n## Evidence Supporting the Hypothesis\n1. Caloric restriction improves cognitive performance and restores circadian patterns of neurotrophic, clock, and epigenetic factors. Identifier 39447038. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n2. Sirtuin modulators have established therapeutic potential. Identifier 21879453. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n3. HDAC inhibitors show promise for healthy aging. Identifier 31368626. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n4. Memorable food interventions can fight age-related neurodegeneration through precision nutrition. Identifier 34422879. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n5. Sirtuin family in autoimmune diseases. Identifier 37483618. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n6. PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis. Identifier 39570804. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.\n\n## Contradictory Evidence, Caveats, and Failure Modes\n1. Exercise orchestrates systemic metabolic and neuroimmune homeostasis via the brain-muscle-liver axis to slow down aging and neurodegeneration: a narrative review. Identifier 40506775. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n2. Nicotinamide N-methyltransferase as a potential therapeutic target for neurodegenerative disorders: Mechanisms, challenges, and future directions. Identifier 40221009. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n3. Protective effects of CHIP overexpression and Wharton's jelly mesenchymal-derived stem cell treatment against streptozotocin-induced neurotoxicity in rats. Identifier 35442559. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n4. Mammalian nucleophagy: process and function. Identifier 39827882. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n5. Hippocampus and its involvement in Alzheimer's disease: a review. Identifier 35116217. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.\n\n## Clinical and Translational Relevance\nFrom a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.8349`, debate count `3`, citations `52`, predictions `4`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.\n1. Trial context: Completed. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n2. Trial context: Recruiting. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\n3. Trial context: Completed. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.\nFor Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.\n\n## Experimental Predictions and Validation Strategy\nFirst, the hypothesis should be decomposed into a perturbation experiment that directly manipulates SIRT1 in a model matched to neurodegeneration. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto \"Nutrient-Sensing Epigenetic Circuit Reactivation\".\nSecond, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.\nThird, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.\nFourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.\n\n## Decision-Oriented Summary\nIn summary, the operational claim is that targeting SIRT1 within the disease frame of neurodegeneration can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.",
  "target_gene": "SIRT1",
  "target_pathway": "Sirtuin-1 / NAD+ metabolism / deacetylation",
  "disease": "neurodegeneration",
  "hypothesis_type": "mechanistic",
  "status": "promoted",
  "confidence_score": 0.85,
  "novelty_score": 0.58,
  "feasibility_score": 0.74,
  "impact_score": 0.68,
  "composite_score": 0.700258,
  "mechanistic_plausibility_score": 0.79,
  "druggability_score": 0.9,
  "safety_profile_score": 0.8,
  "evidence_for": [
    {
      "pmid": "39447038",
      "year": "2024",
      "claim": "Caloric restriction improves cognitive performance and restores circadian patterns of neurotrophic, clock, and epigenetic factors",
      "source": "J Gerontol A Biol Sci Med Sci",
      "abstract": "Aging is a complex multifactorial process that results in a general functional decline, including cognitive impairment. Caloric restriction (CR) can positively influence the aging processes and delay cognitive decline. There is a rhythmic variation in memory and learning processes throughout the day, indicating the involvement of the circadian clock in the regulation of these processes. Despite growing evidence on the efficacy of CR, it has not yet been fully determined whether starting this strategy at an advanced age is beneficial for improving quality of life and eventually, for protection against age-related diseases. Here, we investigated the effect of late-onset CR on the temporal organization of the molecular clock machinery, molecules related to cognitive processes and epigenetic regulation, in the hippocampus of old male rats maintained under constant darkness conditions. Our results evidenced the existence of a highly coordinated temporal organization of Bmal1, Clock, Bdnf, T",
      "strength": "medium"
    },
    {
      "pmid": "21879453",
      "year": "2011",
      "claim": "Sirtuin modulators have established therapeutic potential",
      "source": "Handb Exp Pharmacol",
      "abstract": "Members of the sirtuin family including the founding protein Sir2 in Saccharomyces cerevisiae have been linked to lifespan extension in simple organisms. This finding prompted evaluation of the role of Sir2 orthologues in many aging-associated conditions including neurodegeneration, type II diabetes and cancer. These studies have demonstrated that genetic and pharmacologic manipulation of sirtuin activity have beneficial effects in a surprisingly broad spectrum of aging-associated conditions suggesting that the Sir2-family of enzymes presents an attractive target for the development of pharmacological agents. While the initial model favored pharmacological activators of sirtuins as calorie restriction mimetics, it now appears that either activation or inhibition of sirtuins may be desirable for ameliorating disease depending on the pathological condition and the target tissue. In this chapter we review the development of pharmacological small molecule activators and inhibitors of the s",
      "strength": "medium"
    },
    {
      "pmid": "31368626",
      "year": "2019",
      "claim": "HDAC inhibitors show promise for healthy aging",
      "source": "EMBO Mol Med",
      "abstract": "Reversing or slowing the aging process brings great promise to treat or prevent age-related disease, and targeting the hallmarks of aging is a strategy to achieve this. Epigenetics affects several if not all of the hallmarks of aging and has therefore emerged as a central target for intervention. One component of epigenetic regulation involves histone deacetylases (HDAC), which include the \"classical\" histone deacetylases (of class I, II, and IV) and sirtuin deacetylases (of class III). While targeting sirtuins for healthy aging has been extensively reviewed elsewhere, this review focuses on pharmacologically inhibiting the classical HDACs to promote health and longevity. We describe the theories of how classical HDAC inhibitors may operate to increase lifespan, supported by studies in model organisms. Furthermore, we explore potential mechanisms of how HDAC inhibitors may have such a strong grasp on health and longevity, summarizing their links to other hallmarks of aging. Finally, we",
      "strength": "medium"
    },
    {
      "pmid": "34422879",
      "year": "2021",
      "claim": "Memorable food interventions can fight age-related neurodegeneration through precision nutrition",
      "source": "Front Nutr",
      "abstract": "Healthcare systems worldwide are seriously challenged by a rising prevalence of neurodegenerative diseases (NDDs), which mostly, but not exclusively, affect the ever-growing population of the elderly. The most known neurodegenerative diseases are Alzheimer's (AD) and Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis, but some viral infections of the brain and traumatic brain injury may also cause NDD. Typical for NDD are the malfunctioning of neurons and their irreversible loss, which often progress irreversibly to dementia and ultimately to death. Numerous factors are involved in the pathogenesis of NDD: genetic variability, epigenetic changes, extent of oxidative/nitrosative stress, mitochondrial dysfunction, and DNA damage. The complex interplay of all the above-mentioned factors may be a fingerprint of neurodegeneration, with different diseases being affected to different extents by particular factors. There is a voluminous body of evidence showing the bene",
      "strength": "medium"
    },
    {
      "pmid": "37483618",
      "year": "2023",
      "claim": "Sirtuin family in autoimmune diseases.",
      "source": "Front Immunol",
      "abstract": "In recent years, epigenetic modifications have been widely researched. As humans age, environmental and genetic factors may drive inflammation and immune responses by influencing the epigenome, which can lead to abnormal autoimmune responses in the body. Currently, an increasing number of studies have emphasized the important role of epigenetic modification in the progression of autoimmune diseases. Sirtuins (SIRTs) are class III nicotinamide adenine dinucleotide (NAD)-dependent histone deacetylases and SIRT-mediated deacetylation is an important epigenetic alteration. The SIRT family comprises seven protein members (namely, SIRT1-7). While the catalytic core domain contains amino acid residues that have remained stable throughout the entire evolutionary process, the N- and C-terminal regions are structurally divergent and contribute to differences in subcellular localization, enzymatic activity and substrate specificity. SIRT1 and SIRT2 are localized in the nucleus and cytoplasm. SIRT",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "39570804",
      "year": "2025",
      "claim": "PTBP1 Lactylation Promotes Glioma Stem Cell Maintenance through PFKFB4-Driven Glycolysis.",
      "source": "Cancer Res",
      "abstract": "Long-standing evidence implicates glioma stem cells (GSC) as the major driver for glioma propagation and recurrence. GSCs have a distinctive metabolic landscape characterized by elevated glycolysis. Lactate accumulation resulting from enhanced glycolytic activity can drive lysine lactylation to regulate protein functions, suggesting that elucidating the lactylation landscape in GSCs could provide insights into glioma biology. Herein, we have demonstrated that global lactylation was significantly elevated in GSCs compared with differentiated glioma cells. Polypyrimidine tract-binding protein 1 (PTBP1), a central regulator of RNA processing, was hyperlactylated in GSCs, and SIRT1 induced PTBP1 delactylation. PTBP1-K436 lactylation supported glioma progression and GSC maintenance. Mechanistically, K436 lactylation inhibited PTBP1 proteasomal degradation by attenuating the interaction with TRIM21. Moreover, PTBP1 lactylation enhanced RNA-binding capacity and facilitated PFKFB4 mRNA stabili",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "33770194",
      "year": "2021",
      "claim": "Fasting and fasting-mimicking treatment activate SIRT1/LXRα and alleviate diabetes-induced systemic and microvascular dysfunction.",
      "source": "Diabetologia",
      "abstract": "AIMS/HYPOTHESIS: Homo sapiens evolved under conditions of intermittent food availability and prolonged fasting between meals. Periods of fasting are important for recovery from meal-induced oxidative and metabolic stress, and tissue repair. Constant high energy-density food availability in present-day society contributes to the pathogenesis of chronic diseases, including diabetes and its complications, with intermittent fasting (IF) and energy restriction shown to improve metabolic health. We have previously demonstrated that IF prevents the development of diabetic retinopathy in a mouse model of type 2 diabetes (db/db); however the mechanisms of fasting-induced health benefits and fasting-induced risks for individuals with diabetes remain largely unknown. Sirtuin 1 (SIRT1), a nutrient-sensing deacetylase, is downregulated in diabetes. In this study, the effect of SIRT1 stimulation by IF, fasting-mimicking cell culture conditions (FMC) or pharmacological treatment using SRT1720 was eva",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "38279580",
      "year": "2024",
      "claim": "Innate Immune Training Initiates Efferocytosis to Protect against Lung Injury.",
      "source": "Adv Sci (Weinh)",
      "abstract": "Innate immune training involves myelopoiesis, dynamic gene modulation, and functional reprogramming of myeloid cells in response to secondary heterologous challenges. The present study evaluates whether systemic innate immune training can protect tissues from local injury. Systemic pretreatment of mice with β-glucan, a trained immunity agonist, reduces the mortality rate of mice with bleomycin-induced lung injury and fibrosis, as well as decreasing collagen deposition in the lungs. β-Glucan pretreatment induces neutrophil accumulation in the lungs and enhances efferocytosis. Training of mice with β-glucan results in histone modification in both alveolar macrophages (AMs) and neighboring lung epithelial cells. Training also increases the production of RvD1 and soluble mediators by AMs and efferocytes. Efferocytosis increases trained immunity in AMs by stimulating RvD1 release, thus inducing SIRT1 expression in neighboring lung epithelial cells. Elevated epithelial SIRT1 expression is as",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "35002516",
      "year": "2022",
      "claim": "Regulation of lung epithelial cell senescence in smoking-induced COPD/emphysema by microR-125a-5p via Sp1 mediation of SIRT1/HIF-1a.",
      "source": "Int J Biol Sci",
      "abstract": "Chronic obstructive pulmonary disease (COPD) affects the health of more than 300 million people worldwide; at present, there is no effective drug to treat COPD. Smoking is the most important risk factor, but the molecular mechanism by which smoking causes the disease is unclear. The senescence of lung epithelial cells is related to development of COPD. Regulation of miRNAs is the main epigenetic mechanism related to aging. β-Galactose staining showed that the lung tissues of smokers have a higher degree of cellular senescence, and the expression of miR-125a-5p is high. This effect is obvious for smokers with COPD/emphysema, and there is a negative correlation between miR-125a-5p levels and values for forced expiratory volume in one second (FEV1)/forced vital capacity (FVC). After Balb/c mice were chronically exposed to various concentrations of cigarette smoke (CS), plethysmography showed that lung function was impaired, lung tissue senescence was increased, and the senescence-associat",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "37456463",
      "year": "2023",
      "claim": "The Role of Sirtuin 1 (SIRT1) in Neurodegeneration.",
      "source": "Cureus",
      "abstract": "Sirtuins (SIRT) are a class of histone deacetylases that regulate important metabolic pathways and play a role in several disease processes. Of the seven mammalian homologs currently identified, sirtuin 1 (SIRT1) is the best understood and most studied. It has been associated with several neurodegenerative diseases and cancers. As such, it has been further investigated as a therapeutic target in the treatment of disorders such as Parkinson's disease (PD), Huntington's disease (HD), and Alzheimer's disease (AD). SIRT1 deacetylates histones such as H1 lysine 26, H3 lysine 9, H3 lysine 56, and H4 lysine 16 to regulate chromatin remodeling and gene transcription. The homolog has also been observed to express contradictory responses to tumor suppression and tumor promotion. Studies have shown that SIRT1 may have anti-inflammatory properties by inhibiting the effects of NF-κB, as well as stimulating upregulation of autophagy. The SIRT1 activators resveratrol and cilostazol have been shown to",
      "strength": "medium"
    },
    {
      "pmid": "39128469",
      "year": "2024",
      "claim": "SIRT1 improves lactate homeostasis in the brain to alleviate parkinsonism via deacetylation and inhibition of PKM2.",
      "source": "Cell Rep Med",
      "abstract": "Sirtuin 1 (SIRT1) is a histone deacetylase and plays diverse functions in various physiological events, from development to lifespan regulation. Here, in Parkinson's disease (PD) model mice, we demonstrated that SIRT1 ameliorates parkinsonism, while SIRT1 knockdown further aggravates PD phenotypes. Mechanistically, SIRT1 interacts with and deacetylates pyruvate kinase M2 (PKM2) at K135 and K206, thus leading to reduced PKM2 enzyme activity and lactate production, which eventually results in decreased glial activation in the brain. Administration of lactate in the brain recapitulates PD-like phenotypes. Furthermore, increased expression of PKM2 worsens PD symptoms, and, on the contrary, inhibition of PKM2 by shikonin or PKM2-IN-1 alleviates parkinsonism in mice. Collectively, our data indicate that excessive lactate in the brain might be involved in the progression of PD. By improving lactate homeostasis, SIRT1, together with PKM2, are likely drug targets for developing agents for the t",
      "strength": "medium"
    },
    {
      "pmid": "25281273",
      "year": "2015",
      "claim": "Role of SIRT1 in autoimmune demyelination and neurodegeneration.",
      "source": "Immunol Res",
      "abstract": "Multiple sclerosis (MS) is a demyelinating disease characterized by chronic inflammation of the central nervous system, in which many factors can act together to influence disease susceptibility and progression. SIRT1 is a member of the histone deacetylase class III family of proteins and is an NAD(+)-dependent histone and protein deacetylase. SIRT1 can induce chromatin silencing through the deacetylation of histones and plays an important role as a key regulator of a wide variety of cellular and physiological processes including DNA damage, cell survival, metabolism, aging, and neurodegeneration. It has gained a lot of attention recently because many studies in animal models of demyelinating and neurodegenerative diseases have shown that SIRT1 induction can ameliorate the course of the disease. SIRT1 expression was found to be decreased in the peripheral blood mononuclear cells of MS patients during relapses. SIRT1 represents a possible biomarker of relapses and a potential new target",
      "strength": "medium"
    },
    {
      "pmid": "32985464",
      "year": "2021",
      "claim": "Targeting the core of neurodegeneration: FoxO, mTOR, and SIRT1.",
      "source": "Neural Regen Res",
      "abstract": "The global increase in lifespan noted not only in developed nations, but also in large developing countries parallels an observed increase in a significant number of non-communicable diseases, most notable neurodegenerative disorders. Neurodegenerative disorders present a number of challenges for treatment options that do not resolve disease progression. Furthermore, it is believed by the year 2030, the services required to treat cognitive disorders in the United States alone will exceed $2 trillion annually. Mammalian forkhead transcription factors, silent mating type information regulation 2 homolog 1 (Saccharomyces cerevisiae), the mechanistic target of rapamycin, and the pathways of autophagy and apoptosis offer exciting avenues to address these challenges by focusing upon core cellular mechanisms that may significantly impact nervous system disease. These pathways are intimately linked such as through cell signaling pathways involving protein kinase B and can foster, sometimes in ",
      "strength": "medium"
    },
    {
      "pmid": "23417962",
      "year": "2013",
      "claim": "SIRT1 and SIRT2: emerging targets in neurodegeneration.",
      "source": "EMBO Mol Med",
      "abstract": "Sirtuins are NAD-dependent protein deacetylases known to have protective effects against age-related diseases such as cancer, diabetes, cardiovascular and neurodegenerative diseases. In mammals, there are seven sirtuins (SIRT1-7), which display diversity in subcellular localization and function. While SIRT1 has been extensively investigated due to its initial connection with lifespan extension and involvement in calorie restriction, important biological and therapeutic roles of other sirtuins have only recently been recognized. Here, we review the potential roles and effects of SIRT1 and SIRT2 in neurodegenerative diseases. We discuss different functions and targets of SIRT1 and SIRT2 in a variety of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's Disease (HD). We also cover the role of SIRT1 in neuronal differentiation due to the possible implications in neurodegenerative conditions, and conclude with an outlook on the potential",
      "strength": "medium"
    },
    {
      "pmid": "33852912",
      "year": "2021",
      "claim": "Reducing acetylated tau is neuroprotective in brain injury.",
      "source": "Cell",
      "abstract": "Traumatic brain injury (TBI) is the largest non-genetic, non-aging related risk factor for Alzheimer's disease (AD). We report here that TBI induces tau acetylation (ac-tau) at sites acetylated also in human AD brain. This is mediated by S-nitrosylated-GAPDH, which simultaneously inactivates Sirtuin1 deacetylase and activates p300/CBP acetyltransferase, increasing neuronal ac-tau. Subsequent tau mislocalization causes neurodegeneration and neurobehavioral impairment, and ac-tau accumulates in the blood. Blocking GAPDH S-nitrosylation, inhibiting p300/CBP, or stimulating Sirtuin1 all protect mice from neurodegeneration, neurobehavioral impairment, and blood and brain accumulation of ac-tau after TBI. Ac-tau is thus a therapeutic target and potential blood biomarker of TBI that may represent pathologic convergence between TBI and AD. Increased ac-tau in human AD brain is further augmented in AD patients with history of TBI, and patients receiving the p300/CBP inhibitors salsalate or difl",
      "strength": "medium"
    },
    {
      "pmid": "41268687",
      "year": "2025",
      "claim": "AMPK/SIRT1/PGC-1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies From Energy Homeostasis Regulation to Disease Therapy.",
      "source": "CNS Neurosci Ther",
      "abstract": "BACKGROUND: The AMPK/SIRT1/PGC-1α pathway serves as a central regulator of cellular energy homeostasis, coordinating metabolic stress responses, epigenetic modifications, and transcriptional programs. Its dysfunction is implicated in the pathogenesis of a wide spectrum of complex modern diseases, spanning neurodegeneration, metabolic syndromes, and chronic inflammatory conditions. This review examines the pathway's role as an integrative hub and its potential as a therapeutic target. METHODS: We synthesize current mechanistic evidence from molecular, cellular, and preclinical studies to elucidate the pathway's operational logic and the consequences of its dysregulation. The analysis is structured around key disease paradigms-including Alzheimer's disease, Parkinson's disease, diabetes, cardiovascular injury, stroke, and chronic kidney disease-to dissect its tissue-specific pathophysiological impacts. RESULTS: The AMPK/SIRT1/PGC-1α axis operates through a core positive feedback loop: AM",
      "strength": "medium"
    },
    {
      "pmid": "41915008",
      "year": "2026",
      "claim": "NAD+ subcellular partitioning mediated by miR-183 and miR-96 regulates muscle stem cell differentiation.",
      "source": "J Mol Cell Biol",
      "abstract": "The intracellular abundance of NAD+, a vital metabolic cofactor, critically influences muscle stem cell (MuSC) function. However, the spatial regulation of NAD+ and its impact on MuSC function remain unclear. In this study, we demonstrated that the loss of miR-183 and miR-96 leads to inefficient skeletal muscle regeneration upon injury and triggers premature differentiation of MuSC-derived primary myoblasts. The underlying mechanism involves miRNA-mediated regulation through targeting SLC25A51, a mitochondrial transporter for NAD+ that elevates mitochondrial NAD+ while reducing cytoplasmic NAD+ levels. Our results suggest that the reduction in cytoplasmic NAD+ diminishes SIRT1-mediated deacetylation, increasing H4K16ac at the promoters of myogenic genes to promote differentiation. Concurrently, the mitochondrial NAD+ accumulation stimulates the tricarboxylic acid cycle, leading to elevated levels of ATP and citrate. These metabolites allosterically activate the ACLY pathway, which in t",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41898317",
      "year": "2026",
      "claim": "All the Way: A Decade of SIRT1 in Breast Cancer.",
      "source": "Biomedicines",
      "abstract": "Breast cancer (BC) is a highly heterogeneous genetic disease, comprising several subtypes with distinct features that significantly influence prognosis and treatment outcomes. Among these subtypes, triple-negative breast cancer (TNBC) is particularly aggressive and makes it resistant to many standard therapies. Epigenetic mechanisms, including acetylation and deacetylation, are crucial in regulating gene expression and maintaining normal cellular functions and are closely associated with BC progression. In this context, the histone deacetylases sirtuins (SIRT1-7) regulate key biological processes like genomic stability, inflammation, cellular senescence, and metabolic functions, increasingly linked to cancer. In particular, SIRT1 shows dual roles, functioning both as a tumor suppressor or an oncogene, contributing to cancer initiation, progression, and metastasis as well as chemotherapy resistance. Despite extensive research in the past decade, the exact role of SIRT1 in BC, especially",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41880654",
      "year": "2026",
      "claim": "Urolithin A Reverses Intranigral Rotenone-Generated Parkinsonism by Modulating DNA Methyltransferase 1 and α-Synuclein Axis in Rats.",
      "source": "ACS Chem Neurosci",
      "abstract": "Epigenetic aberrations play a key role in the neuropathogenesis of Parkinson's disease (PD). Herein, we explored the post-translational changes of DNA methyltransferase 1 (DNMT1), an epigenetic marker, in a rotenone model of PD. Rats infused with intranigral rotenone showed impaired locomotor activity and motor coordination in open-field, rotarod, and gait assays. We also noted a depression-like phenotype in the forced swim test (FST). These rotenone-generated motor and nonmotor abnormalities were reversed following peroral administration of urolithin A (UA) at 50 and 100 mg/kg doses. At the molecular level, decreased mRNA/protein expression of the NAD+-dependent sirtuin 1 (SIRT1) enzyme was seen in the substantia nigra (SN) of the rotenone-infused group. At the epigenetic level, we observed a decreased expression of DNMT1 and upregulated levels of acetylated DNMT1 (ac-DNMT1) in the SN of rotenone-recipient rats. UA treatment elevated the SIRT1 expression and DNMT1 deacetylation in the",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41877258",
      "year": "2026",
      "claim": "Uncovering the metabolic-epigenetic links between gene expression and stroke: insights from lactylation pathway MR study.",
      "source": "Neurol Res Pract",
      "abstract": "BACKGROUND: Lactylation, a novel post-translational modification driven by lactate accumulation, has been implicated in neuroinflammation and metabolic stress. However, its causal relevance to ischemic stroke (IS) and its subtypes—large artery stroke (LAS), cardioembolic stroke (CES), and small vessel stroke (SVS)—remains unknown. METHODS: We conducted a two-sample Mendelian randomization (TSMR) analysis to investigate the causal relationships between lactylation-associated gene expression and IS risk. Lactylation-related genes were identified from a recent literature review and intersected with eQTL data from the eQTLGen Consortium (n = 31,684). Summary statistics for IS and its subtypes were obtained from large-scale GWAS (total cases = 62,100; controls = 1,234,808). Primary analyses used the inverse-variance weighted (IVW) method, complemented by MR-Egger, weighted median, and sensitivity tests to assess heterogeneity and pleiotropy. RESULTS: A total of 15 genes and 274 single nucle",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41869013",
      "year": "2026",
      "claim": "Immune-metabolic positive feedback model in COPD: cross-mechanisms and potential intervention strategies.",
      "source": "Front Cell Dev Biol",
      "abstract": "Chronic obstructive pulmonary disease (COPD) is a common chronic condition characterized by chronic bronchitis and/or emphysema with airflow obstruction, which can progress to cor pulmonale and respiratory failure. Associated with abnormal inflammatory responses to harmful gases and particulate matter, it carries high rates of disability and mortality, with a global prevalence among individuals aged 40 and older reaching 9%-10%. It is often regarded as a clinical and molecular model of accelerated lung aging. Age-related drift in immune function and metabolism plays a central part in this process, but how these changes are linked across different biological levels is still not fully clarified. Current work highlights mitochondrial injury and excessive reactive oxygen species as a central node that disrupts energy-sensing pathways, interferes with autophagy and epigenetic control, and weakens mitochondrial biogenesis, together fostering long-term glycolipid imbalance. At the same time, ",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41830033",
      "year": "2026",
      "claim": "Demonstrates how bioactive natural products can modulate autophagy through mechanisms consistent with SIRT1-mediated nutrient sensing pathways.",
      "source": "Nutrients",
      "abstract": "Autophagy is an evolutionarily preserved intracellular degradation process pivotal in maintaining proteostasis, mitochondrial homeostasis, and metabolic equilibrium, all of which are dysregulated with aging. Aberrant autophagy has been recognized as a hallmark of human aging and age-related diseases, including neurodegeneration, metabolic dysfunction, cardiovascular diseases, and cancer. Bioactive natural compounds derived from plants, foods, and marine organisms have emerged as potent modulator",
      "strength": "medium"
    },
    {
      "pmid": "41844011",
      "year": "2026",
      "claim": "Validates oxidative stress-related regulatory genes that align with the hypothesis's focus on SIRT1-mediated metabolic regulation in neurodegeneration.",
      "source": "J Prev Alzheimers Dis",
      "abstract": "Oxidative stress (OS) plays a critical role in the pathogenesis of Alzheimer's disease (AD), yet its genetic and epigenetic regulatory mechanisms remain unclear. In this study, we applied a three-step summary-based Mendelian randomization (SMR) framework to integrate Alzheimer's disease (AD) GWAS summary statistics with peripheral-blood eQTL and mQTL datasets, and further evaluated brain-tissue relevance using GTEx v8 and AMP-AD resources. Across the three-step SMR analyses, we prioritized multi",
      "strength": "medium"
    },
    {
      "pmid": "41879438",
      "year": "2026",
      "claim": "Provides direct evidence of SIRT1-driven mitochondrial biogenesis as a neuroprotective mechanism in neurological injury models.",
      "source": "Curr Neuropharmacol",
      "abstract": "Chronic cerebral ischemia (CCI) induces hippocampal neuronal injury, with mitochondrial dysfunction emerging as a pivotal pathological driver of ischemic brain damage. Enhancing mitochondrial biogenesis (MB) represents a promising reparative strategy to restore neuronal homeostasis. Rhodiola sacra (RS), a traditional Tibetan herb, exhibits neuroprotective potential against ischemic injury; however, its underlying mechanisms, particularly its association with MB, remain unclear. This study aims t",
      "strength": "medium"
    },
    {
      "pmid": "41759326",
      "year": "2026",
      "claim": "Explores insulin resistance and SIRT1 dysregulation, directly supporting the hypothesis's core mechanism of nutrient-sensing circuit disruption.",
      "source": "Ageing Res Rev",
      "abstract": "Metabolic diseases such as Type 2 Diabetes, obesity, and metabolic syndrome are increasing worldwide in parallel with neurodegenerative disorders, yet a unifying biological framework linking systemic metabolic dysfunction to progressive neuronal loss is still lacking. Existing models remain fragmented, focusing on disease-specific mechanisms rather than the shared metabolic vulnerability of the brain. Here, we propose an insulin resistance-Sirtuin 1 collapse axis as a unifying metabolic paradigm",
      "strength": "medium"
    },
    {
      "pmid": "41863647",
      "year": "2026",
      "claim": "Highlights dysregulation of SIRT1 in aging and cancer, supporting the hypothesis's central mechanism.",
      "source": "Amino Acids",
      "abstract": "Interest in RNA editing has emerged in molecular medicine due to its widespread dysregulation and therapeutic potential. Its regulatory mechanisms in governing non-coding RNAs, especially microRNAs (miRNAs) remain largely unresolved. Emerging evidence in diseases reveals a functional convergence between miRNAs and polyamine metabolism, two systems traditionally studied separately. miRNAs serve as primary substrates for adenosine deaminase acting on RNA (ADAR) which could regulate polyamine metab",
      "strength": "medium"
    },
    {
      "pmid": "41714304",
      "year": "2026",
      "claim": "Investigates sirtuin/FOXO3a cascade in Alzheimer's disease, directly aligning with the proposed nutrient-sensing regulatory network.",
      "source": "J Neurochem",
      "abstract": "Sulfonamide-based compounds have been a clinically attractive scaffold for drug development and proven as antioxidant and antimicrobial agents, but their pharmacological derivatives containing anthranilates (SA1-4) and therapeutic targets are not clearly clarified. To unravel the neuroprotective roles and underlying mechanisms of SA1-4 against oxidative injury and healthy longevity crosstalk, a combination of in vitro experiments, in silico modeling, and network pharmacology was employed. Pretre",
      "strength": "medium"
    },
    {
      "pmid": "41692938",
      "year": "2026",
      "claim": "The paper demonstrates linkages between mitochondrial-epigenetic networks and cellular survival, supporting the hypothesis's core mechanism of metabolic regulation through epigenetic circuits.",
      "source": "Geroscience",
      "abstract": "Sirtuins (SIRT1-SIRT7) are NAD⁺-dependent regulators of mitochondrial metabolism, chromatin remodeling, and stress resilience pathways-processes that are central to both aging biology and breast cancer (BC) heterogeneity. We systematically evaluated their prognostic and transcriptional patterns across molecular subtypes of BC. We constructed an integrated BC dataset comprising gene expression and survival data containing tumors from 55 datasets. Prognostic associations with recurrence-free survi",
      "strength": "medium"
    },
    {
      "pmid": "41645754",
      "year": "2026",
      "claim": "Mechanistic advances in exercise‑mediated regulation of autophagy dysfunction in Alzheimer's disease (Review).",
      "source": "Int J Mol Med"
    },
    {
      "pmid": "41936814",
      "year": "2026",
      "claim": "Valsartan promotes neuroprotection in Parkinson's disease via epigenetic modulation and activation of the ASCL1/Nurr1 pathway.",
      "source": "Life Sci"
    },
    {
      "pmid": "41934491",
      "year": "2026",
      "claim": "SIRT1 Activators as Geroprotective Agents in Brain Aging: Mechanisms and Therapeutic Potential.",
      "source": "Neuromolecular Med"
    },
    {
      "pmid": "41709697",
      "year": "2026",
      "claim": "Loss of REST associated with Alzheimer's disease pathology is ameliorated by NAD.",
      "source": "Brain"
    },
    {
      "pmid": "41946579",
      "year": "2026",
      "claim": "[The Chinese medicine Gandouling attenuates brain injury in hepatolenticular degeneration mice by inhibiting ferroptosis via the SIRT1/FoxO3 pathway].",
      "source": "Zhejiang Da Xue Xue Bao Yi Xue Ban"
    },
    {
      "pmid": "41687709",
      "year": "2026",
      "claim": "Unravelling the therapeutic potential of chrysin against ischemic stroke and post-stroke cognitive impairment: a network pharmacology and in-silico perspective.",
      "source": "Neuroscience"
    }
  ],
  "evidence_against": [
    {
      "pmid": "40506775",
      "year": "2025",
      "claim": "Exercise orchestrates systemic metabolic and neuroimmune homeostasis via the brain-muscle-liver axis to slow down aging and neurodegeneration: a narrative review",
      "source": "Eur J Med Res",
      "abstract": "Aging is a systemic process marked by progressive multi-organ dysfunction, metabolic dysregulation, and chronic low-grade inflammation (\"inflammaging\"), which collectively drive neurodegenerative diseases such as Alzheimer's Disease (AD) and Parkinson's Disease (PD). Emerging evidence underscores the brain-muscle-liver axis as a central hub for maintaining energy homeostasis and neuroimmune crosstalk during aging. Here, we elucidate how exercise orchestrates inter-organ communication to counteract age-related decline through metabolic reprogramming, immunomodulation, and neuroprotection. Mechanistically, exercise enhances mitochondrial biogenesis and oxidative capacity in skeletal muscle via AMPK/PGC-1α signaling, restoring fatty acid oxidation and glucose metabolism while producing myokines (e.g., BDNF and IL-6) that promote neuronal survival and synaptic plasticity. Concurrently, hepatic SIRT1 activation promotes lipid metabolism, mitigates insulin resistance, and reduces systemic in",
      "strength": "medium"
    },
    {
      "pmid": "40221009",
      "year": "2025",
      "claim": "Nicotinamide N-methyltransferase as a potential therapeutic target for neurodegenerative disorders: Mechanisms, challenges, and future directions",
      "source": "Exp Neurol",
      "abstract": "Neurodegenerative diseases (NDs), including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD), are characterized by progressive neuronal loss and functional decline, posing significant global health challenges. Emerging evidence highlights nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme regulating nicotinamide (NAM) methylation, as a pivotal player in NDs through its dual impact on epigenetic regulation and metabolic homeostasis. This review synthesizes current knowledge on NNMT's role in disease pathogenesis, focusing on its epigenetic modulation via DNA hypomethylation and histone modifications, alongside its disruption of NAD+ synthesis and homocysteine (Hcy) metabolism. Elevated NNMT activity depletes NAD+, exacerbating mitochondrial dysfunction and impairing energy metabolism, while increased Hcy levels drive oxidative stress, neuroinflammation, and aberrant protein aggregation (e.g., Aβ, tau, α-synuclein). Notably, NNMT overexpression i",
      "strength": "medium"
    },
    {
      "pmid": "35442559",
      "year": "2022",
      "claim": "Protective effects of CHIP overexpression and Wharton's jelly mesenchymal-derived stem cell treatment against streptozotocin-induced neurotoxicity in rats",
      "source": "Environ Toxicol",
      "abstract": "Diabetic neuropathy is a common complication of diabetes mellitus, posing a challenge in treatment. Previous studies have indicated the protective role of mesenchymal stem cells against several disorders. Although they can repair nerve injury, their key limitation is that they reduce viability under stress conditions. We recently observed that overactivation of the carboxyl terminus of heat shock protein 70 (Hsp70) interacting protein (CHIP) considerably rescued cell viability under hyperglycemic stress and played an essential role in promoting the beneficial effects of Wharton's jelly-derived mesenchymal stem cells (WJMSCs). Thus, the present study was designed to unveil the protective effects of CHIP-overexpressing WJMSCs against neurodegeneration using in vivo animal model based study. In this study, western blotting observed that CHIP-overexpressing WJMSCs could rescue nerve damage observed in streptozotocin-induced diabetic rats by activating the AMPKα/AKT and PGC1α/SIRT1 signalin",
      "strength": "medium"
    },
    {
      "pmid": "39827882",
      "year": "2025",
      "claim": "Mammalian nucleophagy: process and function.",
      "source": "Autophagy",
      "abstract": "The nucleus is a highly specialized organelle that houses the cell's genetic material and regulates key cellular activities, including growth, metabolism, protein synthesis, and cell division. Its structure and function are tightly regulated by multiple mechanisms to ensure cellular integrity and genomic stability. Increasing evidence suggests that nucleophagy, a selective form of autophagy that targets nuclear components, plays a critical role in preserving nuclear integrity by clearing dysfunctional nuclear materials such as nuclear proteins (lamins, SIRT1, and histones), DNA-protein crosslinks, micronuclei, and chromatin fragments. Impaired nucleophagy has been implicated in aging and various pathological conditions, including cancer, neurodegeneration, autoimmune disorders, and neurological injury. In this review, we focus on nucleophagy in mammalian cells, discussing its mechanisms, regulation, and cargo selection, as well as evaluating its therapeutic potential in promoting human",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "35116217",
      "year": "2022",
      "claim": "Hippocampus and its involvement in Alzheimer's disease: a review.",
      "source": "3 Biotech",
      "abstract": "Hippocampus is the significant component of the limbic lobe, which is further subdivided into the dentate gyrus and parts of Cornu Ammonis. It is the crucial region for learning and memory; its sub-regions aid in the generation of episodic memory. However, the hippocampus is one of the brain areas affected by Alzheimer's (AD). In the early stages of AD, the hippocampus shows rapid loss of its tissue, which is associated with the functional disconnection with other parts of the brain. In the progression of AD, atrophy of medial temporal and hippocampal regions are the structural markers in magnetic resonance imaging (MRI). Lack of sirtuin (SIRT) expression in the hippocampal neurons will impair cognitive function, including recent memory and spatial learning. Proliferation, differentiation, and migrations are the steps involved in adult neurogenesis. The microglia in the hippocampal region are more immunologically active than the other regions of the brain. Intrinsic factors like hormon",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "24624331",
      "year": "2014",
      "claim": "Role of advanced glycation end products in cellular signaling.",
      "source": "Redox Biol",
      "abstract": "Improvements in health care and lifestyle have led to an elevated lifespan and increased focus on age-associated diseases, such as neurodegeneration, cardiovascular disease, frailty and arteriosclerosis. In all these chronic diseases protein, lipid or nucleic acid modifications are involved, including cross-linked and non-degradable aggregates, such as advanced glycation end products (AGEs). Formation of endogenous or uptake of dietary AGEs can lead to further protein modifications and activation of several inflammatory signaling pathways. This review will give an overview of the most prominent AGE-mediated signaling cascades, AGE receptor interactions, prevention of AGE formation and the impact of AGEs during pathophysiological processes.",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41902653",
      "year": "2026",
      "claim": "Microglial Activation Under Hypoxic Conditions in Early Alzheimer's Disease: Can Natural SIRT1 Activators Be Therapeutic Allies in the Inflammation-Energy Axis?",
      "source": "Phytother Res",
      "abstract": "Alzheimer's disease (AD) is a progressive neurodegenerative condition characterized by a preclinical stage that typically lasts for decades. Early on during this time, microglia react to pathological changes and become protective and even transiently delay neurodegeneration. In contrast, microglia later acquire the typical pro-inflammatory features that contribute to neurodegeneration in advanced disease. Such decades-long time frame is marked by a significant vulnerability to any event able to tip the balance toward inflammatory microglia. Increasing evidence suggests that early life hypoxic events could be risk factors for AD by acting as early triggers of microglial phenotypic transition, especially affecting mitochondrial functions and energy balance. The NAD+-dependent deacetylase SIRT1 could be a valuable target in this context for its anti-inflammatory and anti-aging functions, which include direct modulation of mitochondrial homeostasis. Many natural compounds enriched in Medit",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41894075",
      "year": "2026",
      "claim": "Therapeutic potential of sulforaphane in neurodegenerative diseases: mechanistic Insights into Nrf2, NF-κB, TrkB, SIRT1, MAPK, and JAK/STAT signalling pathways.",
      "source": "Mol Biol Rep",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    },
    {
      "pmid": "41868184",
      "year": "2026",
      "claim": "Advances and Therapeutic Potential of Anthraquinone Compounds in Neurodegenerative Diseases: A Comprehensive Review.",
      "source": "Drug Des Devel Ther",
      "abstract": "BACKGROUND: Rhubarb, traditionally used in China for neurological disorders, has recently attracted considerable scientific attention for its neuroprotective and cerebrovascular benefits. The main therapeutic components of rhubarb are anthraquinones, including emodin, aloe-emodin, chrysophanol, rhein, and physcion. Accumulating experimental evidence indicates that anthraquinones are of importance in neurodegenerative diseases (NDDs), such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and multiple sclerosis. However, as a promising candidate for drug development, the mechanisms by which anthraquinones treat NDDs have not been systematically reviewed. Therefore, this article outlines the anti-neurodegenerative effects of anthraquinones, focusing on their molecular mechanisms. OBJECTIVE: This article reviews recent research progress of anthraquinones in NDDs, focusing on their potential targets and pathways to provide new ideas for the intervention and treatment of ND",
      "added_at": "2026-04-02",
      "added_by": "pubmed_update_pipeline",
      "strength": "medium"
    }
  ],
  "market_price": 0.99
}